ClinicalTrials.gg
Not yet recruitingNCT06222359Updated Jan 24, 2024

Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study

An observational study in Multiple Sclerosis, Depression and Anxiety, sponsored by King's College London. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by King's College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this pre-post observational study is to explore if it is feasible to implement 1) routine mental health screening and b) an online Cognitive Behavioural Therapy (CBT) treatment for anxiety and/or depression (named COMPASS-MS) for people living with Multiple Sclerosis (MS) (PwMS) and co-morbid psychological distress in routine care.

Read the detailed description

The aim of the project is to conduct a feasibility study regarding the implementation of a) routine mental health screening and b) the COMPASS-MS programme as a low-intensity online CBT treatment for anxiety and/or depression in a large English National Health Service (NHS) secondary care MS Clinic.

The intervention will be supported by COMPASS-trained therapists, who will receive supervision from a Clinical Health Psychologist and the Multi-Disciplinary Team (Quantitative Study A). We will also conduct two nested qualitative studies to explore the barriers and facilitators of implementing the COMPASS-MS care pathway locally at King's Hospital (KCH) (Qualitative Study A) and scaling it across Neurology Services outside KCH (Qualitative Study B).

02

Conditions studied

  • Multiple Sclerosis
  • Depression
  • Anxiety
03

In context

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's planned enrollment of 102 is close to the median of 100 across 972 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

People living with Multiple Sclerosis (MS) and co-morbid psychological distress Healthcare professionals and Key stakeholders of people living with MS and co-morbid psychological distress

Eligibility criteria

Patients will be eligible for inclusion for the COMPASS-MS intervention if they are:

  1. Aged ≥18 years
  2. Have a diagnosis of MS.
  3. Speak English to a sufficiently high standard to allow them to interact with digital CBT programmes.
  4. Have access to a computer and email account to allow them to register with the digital CBT programme, and a basic understanding of internet use.
  5. Presence of depression and/or anxiety and/or psychological distress evidenced by:

i. A score of ≥ 5 on the nine item self-report measure of depression: PHQ-9 (Kroenke et al., 2001) AND/OR ii. A score of ≥ 5 on the seven item self-report measure of anxiety: GAD-7 (Spitzer et al., 2006).

OR iii. A score of ≥ 10 on the composite measure of depression and anxiety PHQ-ADS (Kroenke et al., 2016).

AND iv. Distress is related to their MS (i.e. answer "yes" or "sometimes" to "Is your distress linked to your MS?"

The below eligibility criteria apply to HCPs who have experience in engaging with COMPASS-MS care pathways at King's College Hospital (KCH).

Healthcare providers (HCPs) will be eligible for inclusion if they meet all or any of the below criteria:

  1. Work in the Neurology Service at KCH providing care to PwMS
  2. Have experience of either: i) Assessing and triaging patients for psychological distress and/or ii) Providing therapist support to the users of COMPASS-MS.
  3. Work in or alongside KCH who are implementing: i) Routine mental health screening ii) COMPASS digital CBT (e.g. pharmacy/physiotherapy commissioning bodies).

Key Stakeholder Inclusion Criteria

Key Stakeholders from Neurology services external to KCH will be invited to take part in an interview if they meet all or any of the below criteria:

  1. Work in a Neurology Service in England including both inpatient services and MS therapy centres.
  2. Have direct patient experience with working with PwMS (e.g. Neurologist, Doctor, Nurse, Reception)
  3. Work alongside a Neurology services in England and are involved in the care of PwMS (e.g. pharmacy/physiotherapy/commissioning bodies).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No

Interventions

  • DeviceCOMPASS

    Digital CBT to treat psychological distress in Multiple Sclerosis (MS)

06

What researchers measure

Primary outcomes

  1. Psychological Distress (primary outcome for a future full scale trial).

    The investigators will measure general psychological distress using the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This includes 9 items from the Patient Health Questionnaire and 7 items from the Generalised Anxiety Disorder Scale. Each item is responded to on a 4-point Likert Scale (0-3) (minimum score: 0, maximum score: 48). Higher scores indicate higher levels of depression and anxiety.

    Time frame: baseline and 12 week follow up

Secondary outcomes

  1. Reach of screening and COMPASS MS intervention

    - The clinical team will collect data on the route of referral to mental health team (completed routine screening, was referred/self-referred).

    Time frame: Baseline only

  2. Reach of screening and COMPASS MS intervention

    - If referred, the clinical team will collect data on the who the referring clinician is and their professional background.

    Time frame: Baseline only

  3. Reach of screening and COMPASS MS intervention

    - The clinical team will collect data on patient attendance at triage appointment and care pathway recommended (including referral to COMPASS-MS)

    Time frame: Baseline only

  4. Reach of screening and COMPASS MS intervention

    - the clinical team will collect data on the outcome of screening (e.g eligible for COMPASS-MS intervention or not)

    Time frame: Baseline only

  5. Efficacy: psychological outcomes

    - The investigators will measure Intolerance of Uncertainty using the Intolerance of Uncertainty Scale-12 item. Items are rated on a 5-point Likert scale (minimum score: 12, maximum score: 60). Higher scores indicate a greater intolerance of uncertainty.

    Time frame: baseline and 12 week follow up

  6. Efficacy: psychological outcomes

    - The investigators will measure Expression of emotion will be measured using the Beliefs about Emotions Scale.

    Time frame: baseline and 12 week follow up

  7. Efficacy: Psycho-social outcomes

    - The investigators will measure Healthcare usage using the 4 service use items from the Client Service Receipt Inventory (CSRI).

    Time frame: baseline and 12 week follow up

  8. Implementation of COMPASS

    The investigators will investigate the implementation of COMPASS by collecting descriptive data on the number of patients who require digital support to use COMPASS-MS

    Time frame: post treatment (12 week follow up)

  9. Implementation of COMPASS

    The investigators will investigate the implementation of COMPASS by collecting descriptive data on patient adherence to COMPASS online sessions.

    Time frame: post treatment (12 week follow up)

  10. Implementation of COMPASS

    The investigators will investigate the implementation of COMPASS by collecting descriptive data on the number and duration of therapist calls attended.

    Time frame: post treatment (12 week follow up)

  11. Implementation of COMPASS

    The investigators will investigate the implementation of COMPASS by collecting descriptive data on the dropout rate of COMPASS.

    Time frame: post treatment (12 week follow up)

  12. Adoption

    We will qualitatively explore the Adoption of COMPASS. We will conduct two nested qualitative studies. 1) we will interview patients and healthcare professionals at Kings College Hospital to explore the barriers and facilitators of implementing the COMPASS-MS care pathway locally at King's Hospital (KCH) (Qualitative Study A) 2 ) we will interview key stakeholders outside of KCH to explore the barriers and facilitators of scaling it across Neurology Services outside KCH (Qualitative Study B).

    Time frame: 12 weeks follow up (post treatment)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, Monahan PO. Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials. Psychosom Med. 2016 Jul-Aug;78(6):716-27. doi: 10.1097/PSY.0000000000000322. PubMed 27187854 ↗
  • Carleton RN, Norton MA, Asmundson GJ. Fearing the unknown: a short version of the Intolerance of Uncertainty Scale. J Anxiety Disord. 2007;21(1):105-17. doi: 10.1016/j.janxdis.2006.03.014. Epub 2006 May 2. PubMed 16647833 ↗
  • Rimes KA, Chalder T. The Beliefs about Emotions Scale: validity, reliability and sensitivity to change. J Psychosom Res. 2010 Mar;68(3):285-92. doi: 10.1016/j.jpsychores.2009.09.014. Epub 2009 Dec 9. PubMed 20159215 ↗
  • EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9. PubMed 10109801 ↗
  • Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 May;180:461-4. doi: 10.1192/bjp.180.5.461. PubMed 11983645 ↗
  • Ryan EG, Vitoratou S, Goldsmith KA, Chalder T. Psychometric Properties and Factor Structure of a Long and Shortened Version of the Cognitive and Behavioural Responses Questionnaire. Psychosom Med. 2018 Feb/Mar;80(2):230-237. doi: 10.1097/PSY.0000000000000536. PubMed 29023262 ↗
  • Stuifbergen A, Becker H, Blozis S, Beal C. Conceptualization and development of the Acceptance of Chronic Health Conditions Scale. Issues Ment Health Nurs. 2008;29(2):101-14. doi: 10.1080/01612840701792548. PubMed 18293219 ↗
  • Thornicroft, G. (2001). An adapted version of the Client Service Receipt Inventory. Costing psychiatric interventions. London: Measuring Mental Health Needs.
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Feb 2025, 12 months later.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 12 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Jan 24, 2024
StartEst.
Feb 2024
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2025
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222359
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Feb 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
Jan 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion